Infliximab in the treatment of Crohn’s disease

References

• AldersonJWvan DinterTGJrOpatowskyMJDisseminated aspergillosis following Infliximab therapy in an immunosuppressed patient with Crohn’s disease and chronic hepatitis C: a case study and review of the literatureMed Gen Med200577
   PubMedGoogle Scholar
• [ATS] American Thoracic Society, Centers for Disease Control and PreventionCouncil of the infectious disease society of America, September 1999Am J Respir Crit Care Med200016113769510764337
   PubMedGoogle Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med2003348601812584368
   PubMed Web of Science ®Google Scholar
• Beets-TanRGBeetsGLvan der HoopAGPreoperative MR imaging of anal fistulas: does it really help the surgeon?Radiology2001218758411152782
   PubMed Web of Science ®Google Scholar
• BellSJHalliganSWindsorACJResponse of fistulating Crohn’s disease to infliximab treatment assessed by magnetic resonance imagingAliment Pharmacol Ther20031718793
   Google Scholar
• BickstonSJLichtensteinGRArseneauKOThe relationship between infliximab treatment and lymphoma in Crohn’s diseaseGastroenterology199911714333710579985
   PubMed Web of Science ®Google Scholar
• BreeseEMichieCNichollsSTumor necrosis alpha-producting cells in the intestinal mucosa of children with inflammatory bowel diseaseGastroenterology19941061455668194690
   PubMed Web of Science ®Google Scholar
• BrooklynTNDunnillMGShettyAInfliximab for the treatment of Pyoderma Gangrenosum: a randomised, double blind, placebo controlled trialGut200655505916188920
   PubMed Web of Science ®Google Scholar
• Centocor Inc.Product information (EU): Remicade 100mg powder for concentrate for solution for infusion (infliximab 100mg vial) [online]2005a Accessed 10 May 2005. URL: http://www.emea.eu.int
   Google Scholar
• Centocor Inc.Product information (US): Remicade for IV injection (infliximab 100mg vial) [online]2005b Accessed 10 May 2005. URL: http://www.remicade.com
   Google Scholar
• ChenSCCummingsOWHartleyMPHepatocellular carcinoma occurring in a patient with Crohn’s disease treated with both azathioprine and infliximabDig Dis Sci200651952516670938
   PubMedGoogle Scholar
• ColombelJFLoftusEVTremaineWJThe safety profile of Infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patientsGastroenterology2004126193114699483
   PubMed Web of Science ®Google Scholar
• CornillieFShealyDD’HaensGInfliximab induces potent anti-inflammatory and local activity, but no systemic immune suppression in patients with Crohn’s DiseaseAliment Pharmacol Ther2001154637311284774
   PubMed Web of Science ®Google Scholar
• de RidderLEscherJCBouquetJInfliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The NetherlandsJ Pediatr Gastroenterol Nutr200439465215187780
   PubMed Web of Science ®Google Scholar
• DerkxBTaminiauJRademaSTumor-necrosis-factor antibody treatment in Crohn’s diseaseLancet199334217348101267
   PubMed Web of Science ®Google Scholar
• EnayatiPJPapadakisKAAssociation of ant-tumor necrosis factor therapy with the development of multiple sclerosisJ Clin Gastroenterol200539303615758624
   PubMed Web of Science ®Google Scholar
• FarrellRJAlshahliMJeenYTIntravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trialGastroenterology20031249172412671888
   PubMed Web of Science ®Google Scholar
• GuptaGGelfandJMLewisJDIncreased risk for demyelinating diseases in patients with inflammatory bowel diseaseGastroenterology20051298192616143121
   PubMed Web of Science ®Google Scholar
• HaleSLightmanSAnti-TNF therapies in the management of acute and chronic uveitisCytokine200633231716542849
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance Infliximab for Crohn’s Disease: the ACCENT I randomized trialLancet20023591541912047962
   PubMed Web of Science ®Google Scholar
• HanauerSBInflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunitiesInflam Bowel Dis200312Suppl 1S3S9
   Google Scholar
• JoisRNLeederLGibbALow-dose infliximab treatment for Ankylosing Spondylitis: clinically and cost-effectiveRheumatology (Oxford)2006451566916705043
   PubMed Web of Science ®Google Scholar
• KaneSVReddyDInfliximab does not increase the risk of abnormal Pap smears in womenAm J Gastroenterol200499S246
   Google Scholar
• KeaneJGershonSWiseRPTubercolosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345109810411596589
   PubMed Web of Science ®Google Scholar
• KleynCEGriffithsCEInfliximab for the treatment of psoriasisExpert Opin Biol Ther2006679780516856801
   PubMed Web of Science ®Google Scholar
• KugathasanSLevyMBSaeianKInfliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reactionAm J Gastroenterol20029714081412094858
   PubMed Web of Science ®Google Scholar
• LichtensteinGROlsonABaoWInfliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn’s disease patients: ACCENT I study resultsAm J Gastroenterol200297S254
   Google Scholar
• LichtensteinGRYanSBalaMInfliximab mainteinance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s diseaseGastroenterology2005128862915825070
   PubMed Web of Science ®Google Scholar
• LichtigerSHealing of perianal fistulae by local injection of antibody to TNFGastroenterology2001120supplA3154
   Google Scholar
• MarkhamALambHMInfliximab: a review of its use in the management of rheumatoid arthritisDrugs20005913415910882166
   PubMed Web of Science ®Google Scholar
• MitomaHHoriukiTHattaNInfliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-aGastroenterology20051283769215685549
   PubMed Web of Science ®Google Scholar
• NichollsSStephensSBraeggerCPCytokines in stools of children with inflammatory bowel disease or infective diarrheaJ Clin Pathol19934617481
   Google Scholar
• PapadakisKATarganSRTumor necrosis factor: biologic and therapeutic inhibitorsGastroenterology200011911485711040201
   PubMed Web of Science ®Google Scholar
• PoggioliGLauretiSPierangeliFLocal injection of Infliximab for the treatment of perianal Crohn’s diseaseDis Colon Rectum2005487687415768185
   PubMed Web of Science ®Google Scholar
• PoritzLSRoweWAKoltunWARemicade does not abolish the need for surgery in fistulizing Crohn’s diseaseDis Colon Rectum200245771512072629
   PubMedGoogle Scholar
• PresentDHRutgeersPTarganSInfliximab for the treatment of fistulas in patients with Crohn’s DiseaseN Engl J Med1999340139840510228190
   PubMed Web of Science ®Google Scholar
• ReineckerHCSteffenMWitthoeftTEnhanced secretion of tumor necrosis factor-alpha IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s DiseaseClin Exp Immunol199394174818403503
   PubMed Web of Science ®Google Scholar
• Remicade (Infliximab)Prescribing informationPhysician desk reference200155th ed.Montvale, NJThomson Healthcare108588
   Google Scholar
• RispoALemboGInsabatoLSuccessful treatment of therapy-resistant metastatic Crohn’s disease with infliximabBr J Dermatol20041501045615149534
   PubMed Web of Science ®Google Scholar
• RobinsonDMKeatingGMInfliximab: in ankylosing spondylitisDrugs20056512839115916451
   PubMedGoogle Scholar
• RutgeersPVan AsscheGVermeireSOptimizing anti-TNF treatment in inflammatory bowel diseaseGastroenterology2004126159361015168370
   PubMedGoogle Scholar
• RuutgersPFeaganBGLichtensteinGRComparison of scheduled and episodic treatment strategies of Infliximab in Crohn’s diseaseGastroenterology20041264021314762776
   PubMed Web of Science ®Google Scholar
• SachmechianAVasiliauskasEAbreuMMalignancy following remicade therapy: incidence and characteristicsGastroenterology2001120A619
   Google Scholar
• SandbornWJFazioVWFeaganBGAmerican Gastroenterological Association Clinical Practice CommitteeTechnical Review of Perianal Crohn’s DiseaseGastroenterology200312515083014598268
   PubMedGoogle Scholar
• SandbornWJHanauerSBAntitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safetyInflamm Bowel Dis1999511913310338381
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab manteinance therapy for fistulizing Crohn’s diseaseN Engl J Med20043508768514985485
   PubMed Web of Science ®Google Scholar
• SandsBEBlankMADiamondRHMaintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II studyAliment Pharmacol Ther20062311273616611273
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrihnHChimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functionsCytokine1995725197640345
   PubMed Web of Science ®Google Scholar
• SchwartzDAWiersemaMJNortonIDA comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulasGastroenterology200112110647211677197
   PubMed Web of Science ®Google Scholar
• SiddiquiMAAScottLJInfliximab: a review of its use in Crohn’s disease and rheumatoid arthritisDrugs200565217920816225377
   PubMed Web of Science ®Google Scholar
• SpencerJAChappleKWilsonDOutcome after surgery for perianal fistula: predictive value of MR imagingAJR Am J Roentgenol199817140369694464
   PubMed Web of Science ®Google Scholar
• TarganSRHanauerSBDeventerSJA short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s diseaseN Engl J Med19973371029359321530
   PubMed Web of Science ®Google Scholar
• ThomasCWjrWeinshenkerBGSandbornWJDemyelination during anti-tumor necrosis factor alpha therapy with Infliximab for Crohn’s diseaseInflamm Bowel Dis200410283115058523
   PubMed Web of Science ®Google Scholar
• TopstadDRPanaccioneRHeineJACombined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experienceDis Colon Rectum2003465778312792431
   PubMed Web of Science ®Google Scholar
• ToyLSScherlEJKornbluthAComplete bowel obstruction following initial response to infliximab therapy for Crohn’s disease: a series of a newly described complicationGastroenterology2000118supplA569
   Google Scholar
• van AsscheGVanbeckevoortDBielenDMagnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s diseaseAm J Gastroenterol200398332912591051
   PubMed Web of Science ®Google Scholar
• van den BrandeJMHHommesDWPeppelenboschMPInfliximab induced T lymphocyte apoptosis in Crohn’s diseaseJ Rheumatol Suppl200574263015742461
   PubMedGoogle Scholar
• VermeireSNomanMVan AsscheGAutoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort studyGastroenterology200312532912851868
   PubMed Web of Science ®Google Scholar
• WarrisABjorneklettAGaustadPInvasive pulmonary aspergillosis associated with Infliximab therapyN Engl J Med2001344109910011291675
   PubMed Web of Science ®Google Scholar
• WeinbergAMRattanSLewisJDStrictures and response to Infliximab in Crohn’s diseaseAm J Gastroenterol200297S255
   PubMed Web of Science ®Google Scholar
• WesthovensRRahmanMUHanCInfliximab treatment results in a rapid improvement in all aspects of quality of life assessed by the sf-36 in patients with Rheumatoid Arthritis: results from the START trial [abstract]Ann Rheum Dis200564Suppl. III392 FRI0450
   Google Scholar
• WiendlHHohlfeldRTherapeutic approaches in multiple sclerosis: lessons fromfailed and interrupted treatment trialsBio Drugs200216183200
   Google Scholar
• WitthoftTLudwigDEffectiveness and tolerability of repeated treatment with infliximab in patients with Crohn’s disease: a retrospective data analysis in GermanyInt J Colorectal Dis200520182315459773
   PubMedGoogle Scholar